Head and Neck

Clinical Trial NameClinical Trial Full TitlePrincipal InvestigatorProject site statusClinical trials gov number
(GSK) 209229 / INDUCE-3A Randomized, Open-label, Adaptive, Phase II/III Study of Pembrolizumab with or without GSK3359609 for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaMeyers, Dr BrandonOpen to recruitmentNCT04128696
(JCC) SHINE / HNSBRTA Phase 2 Study of SBRT for Squamous Cell Carcinoma of the Head and NeckLee, Dr JustinOpen to recruitmentNCT04435938
(CCTG) HN.9/LA-OSCCRandomized Phase II Study of Cisplatin plus Radiotherapy versus Durvalumab plus Radiotherapy followed by Adjuvant Durvalumab versus Durvalumab plus Radiotherapy followed by Adjuvant Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Cancer (LA-OSCC)Meyers, Dr BrandonRecruitment on hold - COVID-19NCT03410615
(Galera) GTI-4419-301 / ROMANROMAN: Reduction in Oral Mucositis with Avasopasem Manganese (GC4419) – Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck CancerMeyers, Dr BrandonRecruitment on hold - COVID-19NCT03689712
(LHRI) RADIO/Cisplatin Hearing Loss/Cisplatin HD vs LDRandomized Assessment of Cisplatin Dosing Interval for Ototoxicity in the treatment of locally advanced head and neck squamous cell carcinoma (LAHNSCC) undergoing curative concurrent chemoradiotherapy (RADIO)Meyers, Dr BrandonRecruitment on hold - COVID-19NCT03649048
Download PDF